BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 34919024)

  • 21. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis.
    Feng N; Guo Z; Wu X; Tian Y; Li Y; Geng Y; Yu Y
    Respir Res; 2021 Sep; 22(1):248. PubMed ID: 34537072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circ_0011058 facilitates proliferation, angiogenesis and radioresistance in papillary thyroid cancer cells by positively regulating YAP1 via acting as miR-335-5p sponge.
    Zhang Z; Wang W; Su Z; Zhang J; Cao H
    Cell Signal; 2021 Dec; 88():110155. PubMed ID: 34562605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.
    Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z
    Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blocking circ_0010235 suppresses acquired paclitaxel resistance of non-small cell lung cancer by sponging miR-512-5p to modulate FAM83F expression.
    Li Y; Ma Z; Luo M; Liang R
    Anticancer Drugs; 2022 Nov; 33(10):1024-1034. PubMed ID: 36206095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sevoflurane inhibits the malignant phenotypes of glioma through regulating miR-146b-5p/NFIB axis.
    Wang H; Cheng G; Quan L; Qu H; Yang A; Ye J; Feng Y; Li X; Shi X; Pan H
    Metab Brain Dis; 2022 Jun; 37(5):1373-1386. PubMed ID: 35386035
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hsa_circ_0092887 targeting miR-490-5p/UBE2T promotes paclitaxel resistance in non-small cell lung cancer.
    Wang L; Zhang Z; Tian H
    J Clin Lab Anal; 2023 Jan; 37(1):e24781. PubMed ID: 36550019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 28. CircFOXK2 enhances tumorigenesis and immune evasion in non-small cell lung cancer by miR-485-5p/PD-L1 axis.
    Zhang N; Fan J; Deng Z
    Anticancer Drugs; 2022 Jun; 33(5):437-447. PubMed ID: 35324518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CircRNA OXCT1 promotes the malignant progression and glutamine metabolism of non-small cell lung cancer by absorbing miR-516b-5p and upregulating SLC1A5.
    Luo H; Peng J; Yuan Y
    Cell Cycle; 2023 May; 22(10):1182-1195. PubMed ID: 35482822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hsa_circRNA_0017620 regulated cell progression of non-small-cell lung cancer via miR-520a-5p/KRT5 axis.
    Chen S; Hong K; Zhou L; Ran R; Huang J; Zheng Y; Xing M; Cai Y
    J Clin Lab Anal; 2022 Apr; 36(4):e24347. PubMed ID: 35302673
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circular RNA PRMT5 knockdown enhances cisplatin sensitivity and immune response in non-small cell lung cancer by regulating miR-138-5p/MYH9 axis.
    Xu Y; Zhao R; Wang H; Jiang J; Wang Z; Wang J; Zhang W; Li M
    J BUON; 2021; 26(5):1850-1861. PubMed ID: 34761592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CircRNA hsa_circ_0075048 promotes the malignant progression of non-small cell lung cancer by up-regulating HMGB2 expression via targeting miR-1225-5p.
    Zhang J; Mao J
    Histol Histopathol; 2023 Jun; 38(6):709-724. PubMed ID: 36416408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p.
    Dong Y; Xu T; Zhong S; Wang B; Zhang H; Wang X; Wang P; Li G; Yang S
    Life Sci; 2019 Dec; 239():116984. PubMed ID: 31647948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circular RNA CELF1 drives immunosuppression and anti-PD1 therapy resistance in non-small cell lung cancer via the miR-491-5p/EGFR axis.
    Ge W; Chi H; Tang H; Xu J; Wang J; Cai W; Ma H
    Aging (Albany NY); 2021 Nov; 13(22):24560-24579. PubMed ID: 34788230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circular RNA hsa_circ_0011298 enhances Taxol resistance of non-small cell lung cancer by regulating miR-486-3p/CRABP2 axis.
    Wu Y; Xie J; Wang H; Hou S; Feng J
    J Clin Lab Anal; 2022 May; 36(5):e24408. PubMed ID: 35396749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circular RNA circ_0002360 regulates the Taxol resistance and malignant behaviors of Taxol-resistant non-small cell lung cancer cells by microRNA-585-3p-dependent modulation of G protein regulated inducer of neurite outgrowth 1.
    Cui X; Zhang B; Li B; Li X
    Bioengineered; 2022 Apr; 13(4):9070-9085. PubMed ID: 35293280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circular RNA hsa_circ_0014130 Inhibits Apoptosis in Non-Small Cell Lung Cancer by Sponging miR-136-5p and Upregulating BCL2.
    Geng Y; Bao Y; Zhang W; Deng L; Su D; Zheng H
    Mol Cancer Res; 2020 May; 18(5):748-756. PubMed ID: 32060230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circ_0110498 facilitates the cisplatin resistance of non-small cell lung cancer by mediating the miR-1287-5p/RBBP4 axis.
    Hao D; Li Y; Shi J; Jiang J
    Thorac Cancer; 2023 Mar; 14(7):662-672. PubMed ID: 36691322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circular non-coding RNA circ_0072088 serves as a ceRNA, targeting the miR-1225-5p/WT1 axis to regulate non-small cell lung cancer cell malignant behavior.
    Zhu X; Wan J; You X; Yang W; Zhao L
    Thorac Cancer; 2023 Jul; 14(20):1969-1979. PubMed ID: 37220935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Up-regulation of circ_0000353 impedes the proliferation and metastasis of non-small cell lung cancer cells via adsorbing miR-411-5p and increasing forkhead box O1.
    Zhao WX; Tang YL; Wang WH; Bao MW
    Cancer Biomark; 2020; 29(1):25-37. PubMed ID: 32568175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.